PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 15, 2017
Thermo Fisher Scientific to Acquire Patheon
Author(s)Pharmaceutical Technology Editors
Thermo Fisher will acquire Patheon for approximately $7.2 billion, including the assumption of approximately $2 billion of net debt.
Advertisement
On May 15, 2017, Thermo Fisher Scientific announced plans to purchase Patheon for $35 per share in cash. The transaction totals approximately $7.2 billion, which includes the assumption of approximately $2 billion of net debt.
Patheon has a network of facilities, primarily in North America and Europe, and approximately 9000 professionals worldwide. In 2016, Patheon generated approximately $1.9 billion in revenue and will become part of Thermo Fisher's Laboratory Products and Services Segment, the companies said in a
“The combined company's extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities,” the companies noted in a
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5